Current Hypertension Reports

, Volume 5, Issue 5, pp 393–401 | Cite as

Cardiometabolic syndrome: Pathophysiology and treatment

  • Jonathan P. Castro
  • Fadi A. El-Atat
  • Samy I. McFarlane
  • Ashish Aneja
  • James R. Sowers
Article

Abstract

The cardiometabolic syndrome, an interesting constellation of maladaptive cardiovascular, renal, metabolic, prothrombotic, and inflammatory abnormalities, is now recognized as a disease entity by the American Society of Endocrinology, National Cholesterol Education Program, and World Health Organization, among others. These cardiovascular and metabolic derangements individually and interdependently lead to a substantial increase in cardiovascular disease (CVD) morbidity and mortality, making the cardiometabolic syndrome an established and strong risk factor for premature and severe CVD and stroke. Established and evolving treatment strategies including moderate physical activity, weight reduction, rigorous blood pressure control, correction of dyslipidemia, and glycemic control have proven beneficial in reversing these abnormal responses and decreasing the CVD risk.

Keywords

Insulin Resistance Vascular Smooth Muscle Cell Rosiglitazone Blood Pressure Control Impaired Fasting Glucose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Benjamin SM, Valdez R, Geiss LS, et al.: Estimated number of adults with prediabetes in the U.S. in 2000: opportunities for prevention. Diabetes Care 2003, 26:45–649.CrossRefGoogle Scholar
  2. 2.
    Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  3. 3.
    Peiris AN, Sothmann MS, Hoffmann RG, et al.: Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989, 110:867–872.PubMedGoogle Scholar
  4. 4.
    McFarlane SI, Banerji Maryann, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718. This paper is of particular importance in the molecular aspect of the cardiometabolic syndrome and insulin-resistant state. In addition to being written by pioneers in the area of the cardiometabolic syndrome, hyperinsulinemia, and insulin resistance, it carries a wealth of informative illustrations and detailed description of the molecular mechanisms underlying the insulin-resistant state.PubMedCrossRefGoogle Scholar
  5. 5.
    Sowers JR: Update on the cardiometabolic syndrome. Clin Cornerstone 2001, 4:17–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131–141.PubMedCrossRefGoogle Scholar
  7. 7.
    Fontbonne A, Charles MA, Thibult N, et al.: Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991, 34:356–361.PubMedCrossRefGoogle Scholar
  8. 8.
    Ducimetiere P, Eschwege E, Papoz L, et al.: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980, 19:205–210.PubMedCrossRefGoogle Scholar
  9. 9.
    Lamarche B, Tchernof A, Mauriege P, et al.: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955–1961.PubMedCrossRefGoogle Scholar
  10. 10.
    Shinozaki K, Hattori Y, Suzuki M, et al.: Insulin resistance as an independent risk factor for carotid artery wall intima media thickening in vasospastic angina. Arterioscler Thromb Vasc Biol 1997, 7:3302–3310.Google Scholar
  11. 11.
    Meigs JB, D’Agostino RB Sr, Wilson PW, et al.: Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997, 6:1594–1600.CrossRefGoogle Scholar
  12. 12.
    Meigs JB, Mittleman MA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000, 83:221–228.CrossRefGoogle Scholar
  13. 13.
    Brown NJ, Kim KS, Chen YQ, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 5:336–344.CrossRefGoogle Scholar
  14. 14.
    Meade TW, Ruddock V, Stirling Y, et al.: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993, 42:1076–1079.CrossRefGoogle Scholar
  15. 15.
    Thompson SG, Kienast J, Pyke SD, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635–641.PubMedCrossRefGoogle Scholar
  16. 16.
    Freed M, Fuell D, Menci L, et al.: Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia 2000, 43:A267.Google Scholar
  17. 17.
    Fonseca VA, Reynolds T, Hemphill D, et al.: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998, 12:181–186.PubMedCrossRefGoogle Scholar
  18. 18.
    Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 13:1457–1462.PubMedGoogle Scholar
  19. 19.
    Dengel DR, Pratley RE, Hagberg JM, Goldberg AP: Impaired insulin sensitivity and maximal responsiveness in older hypertensive men. Hypertension 1994, 23:320–324.PubMedGoogle Scholar
  20. 20.
    Shen DC, Shieh SM, Fuh MM, et al.: Resistance to insulinstimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988, 66:580–583.PubMedCrossRefGoogle Scholar
  21. 21.
    Williams B: Insulin resistance: the shape of things to come. Lancet 1994, 344:521–524.PubMedCrossRefGoogle Scholar
  22. 22.
    Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374–381.PubMedCrossRefGoogle Scholar
  23. 23.
    Nickenig G, Roling J, Strehlow K, et al.: Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998, 98:2453–2460.PubMedGoogle Scholar
  24. 24.
    Steinberg HO, Chaker H, Leaming R, et al.: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601–2610.PubMedGoogle Scholar
  25. 25.
    Dengel DR, Hagberg JM, Pratley RE, et al.: Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabolism 1998, 47:1075–1082. This paper evaluated the effect of modifying insulin resistance on blood pressure control. It demonstrated a beneficial effect of aerobic exercise training in improving insulin sensitivity and lowering blood pressure among sedentary, nondiabetic, hypertensive subjects.PubMedCrossRefGoogle Scholar
  26. 26.
    Ogihara T, Rakugi H, Ikegami H, et al.: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316–320.PubMedCrossRefGoogle Scholar
  27. 27.
    Raji A, Seely EW, Bekins SA, et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172–178.PubMedCrossRefGoogle Scholar
  28. 28.
    Giordano M, Matsuda M, Sanders L, et al.: Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995, 44:665–671.PubMedCrossRefGoogle Scholar
  29. 29.
    Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B: Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci Lond 1995, 88:629–633.PubMedGoogle Scholar
  30. 30.
    Naidoo DP: The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr 2002, 13:194–199.PubMedGoogle Scholar
  31. 31.
    Donnelly R: Microalbuminuria: a therapeutic goal in patients with type 2 diabetes. Presse Med 2002, 31:S9-S12.PubMedGoogle Scholar
  32. 32.
    Ohashi H, Oda H, Ohno M, Watanabe S: Weight reduction improves high blood pressure and microalbuminuria in hypertensive patients with obesity. Nippon Jinzo Gakkai Shi 2001, 43:333–339.PubMedGoogle Scholar
  33. 33.
    Lozano JV, Llisterri JL, Aznar J, Redon J: Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001, 16:85–89.PubMedCrossRefGoogle Scholar
  34. 34.
    Nakamura T, Ushiyama C, Suzuki S, et al.: Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001, 18:308–313.PubMedCrossRefGoogle Scholar
  35. 35.
    Tonolo G, Ciccarese M, Brizzi P, et al.: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997, 20:1891–1895.PubMedCrossRefGoogle Scholar
  36. 36.
    McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451–1458.PubMedCrossRefGoogle Scholar
  37. 37.
    Smulders YM, van Eeden AE, Stehouwer CD, et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997, 27:997–1002.PubMedCrossRefGoogle Scholar
  38. 38.
    Baron AD, Steinberg HO, Chaker H, et al.: Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995, 96:786–792.PubMedGoogle Scholar
  39. 39.
    Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 1995, 26:869–879.PubMedGoogle Scholar
  40. 40.
    Standley PR, Zhang F, Ram JL, et al.: Insulin attenuates vasopressin-induced calcium transient and voltagedependent calcium response in rat vascular smooth muscle cells. J Clin Invest 1991, 88:1230–1236.PubMedGoogle Scholar
  41. 41.
    Kahn AM, Seidel CL, Allen JC, et al.: Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 1993, 22:735–742.PubMedGoogle Scholar
  42. 42.
    Sowers JR: 1996 Effects of insulin and IGF-I on vascular smooth muscle glucose and cation metabolism. Diabetes 45:S47–S51.Google Scholar
  43. 43.
    Tirupattur PR, Ram JL, Standley PR, Sowers JR: Regulation of Na+, K+-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens 1993, 6:626–629.PubMedGoogle Scholar
  44. 44.
    Gupta S, McArthur C, Grady C, Ruderman NB: Stimulation of vascular Na+-K+-ATPase activity by nitric oxide: a cGMPindependent effect. Am J Physiol 1994, 266:H2146-H2151.PubMedGoogle Scholar
  45. 45.
    Reuter H: Sodium-calcium exchange: ins and outs of Ca2+ transport. Nature 1991, 349:567–568.PubMedCrossRefGoogle Scholar
  46. 46.
    Simmons DA, Winegrad AI: Insulin does not regulate vascular smooth muscle Na+-K+-ATPase activity in rabbit aorta. Diabetologia 1993, 36:2112–2117.CrossRefGoogle Scholar
  47. 47.
    Clausen T, Everts ME: Regulation of the Na, K pump in skeletal muscle. Kidney Int 1989, 35:1–13.PubMedGoogle Scholar
  48. 48.
    Sussman I, Schultz V, Gupta S, et al.: Differential effect of metabolic fuels on the energy state of the Na+,K+-ATPase in isolated cerebral microvessels. Am J Physiol 1993, 265:E777-E782.PubMedGoogle Scholar
  49. 49.
    Tare M, Parkington HA, Coleman HA, et al.: Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature 1990, 346:69–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Husid A, Song T, Kahn AM: Insulin-inhibited Ca2+ influx and contraction of serotonin-stimulated vascular smooth muscle cells is reversed by N-mono-methyl-L-arginine [abstract]. Am J Hypertens 1996, 9:129A.CrossRefGoogle Scholar
  51. 51.
    Trovati M, Massucco P, Mattiello L, et al.: Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetes 1995, 38:936–941.Google Scholar
  52. 52.
    Bakris GL, Palant CE, Walsh MF, Sowers JR: Analogy between endothelial/mesangial cell and endothelial/vascular smooth muscle cell interactions: role of growth factors and mechanotransduction. In Endocrinology of the Vasculature. Edited by Sowers JR. Totowa, NJ: Humana Press; 1996:341–355.Google Scholar
  53. 53.
    Ren J, Samson WK, Sowers JR: Insulin-like growth factor 1 as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999, 31:2049–2061.PubMedCrossRefGoogle Scholar
  54. 54.
    Li D, Sweeney G, Wang Q, Klip A: 1999 Participation of PI3K and atypical PKC in Na+-K+-pump stimulation by IGF-I in VSMC. Am J Physiol 276(6Pt 2):H2109–H2116.Google Scholar
  55. 55.
    Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S. This is a rich and interesting paper on the role of leptin in the cardiometabolic syndrome. It elaborates on the elevation of leptin levels in the obese subjects and its importance in enhancing SNS activity and hence elevated blood pressure.PubMedCrossRefGoogle Scholar
  56. 56.
    Mark AL, Correia M, Morgan DA, et al.: State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999, 3:537–541. This paper sheds the light on the mounting advances into the geneticneurobiologic mechanisms of obesity. It presents a new insight on the sympathetic, vascular, and renal effects of the melanocortin receptor agonists and leptin.Google Scholar
  57. 57.
    Egan BM, Stepniakowski K, Goodfriend TL: Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994, 7:886–893.PubMedGoogle Scholar
  58. 58.
    Goodfriend TL, Egan BM, Kelley DE: Aldosterone in obesity. Endocr Res 1998, 24:789–796.PubMedGoogle Scholar
  59. 59.
    Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401–405.PubMedCrossRefGoogle Scholar
  60. 60.
    Suter PM, Locher R, Hasler E, Vetter W: Is there a role for the ob gene product leptin in essential hypertension? Am J Hypertens 1998, 11:1305–1311.PubMedCrossRefGoogle Scholar
  61. 61.
    Schorr U, Blaschke K, Turan S, et al.: Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998, 16:1475–1480.PubMedCrossRefGoogle Scholar
  62. 62.
    Cooper R, McFarlane Anderson N, Bennett FI, et al.: ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997, 11:107–111.PubMedCrossRefGoogle Scholar
  63. 63.
    Cooper R, Forrester T, Ogunbiyi O, Muffinda J: Angiotensinogen levels and obesity in four black populations. ICSHIB investigators. J Hypertens 1998, 16:571–575.PubMedCrossRefGoogle Scholar
  64. 64.
    Licata G, Scaglione R, Ganguzza A, et al.: Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994, 7:314–320.PubMedGoogle Scholar
  65. 65.
    Uckaya G, Ozata M, Sonmez A, et al.: Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res 1999, 31:435–438.PubMedCrossRefGoogle Scholar
  66. 66.
    Engeli S, Sharma AM: The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001, 79:21–29. This paper is a cornerstone in the subject of enhanced RAAS activity in the cardiometabolic syndrome. It confirms the increased local adipose tissue and systemic RAAS activity in obesity with subsequent involvement in the etiology of obesity-related hypertension.PubMedCrossRefGoogle Scholar
  67. 67.
    Hall JE, Brands MW, Dixon WN, Smith MJ Jr: Obesity-indiced hypertension: renal function and systemic hemodynamics. Hypertension 1993, 22:292–299.PubMedGoogle Scholar
  68. 68.
    Alonso-Galicia M, Brands MW, Zappe DH, Hall JE: Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996, 28:1047–1054.PubMedGoogle Scholar
  69. 69.
    Fadi EA, Aneja A, Mcfarlane S, Sowers J: Obesity and hypertension. Recent Prog Horm Res 2003, In press. This paper is a very thorough review of the maladaptive cardiovascular and metabolic responses to obesity in the cardiometabolic syndrome with a focus on obesity-related hypertension including the pathophysiology and treatment of this entity.Google Scholar
  70. 70.
    Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694–698.PubMedCrossRefGoogle Scholar
  71. 71.
    Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000, 35:1270–1277.PubMedGoogle Scholar
  72. 72.
    Massiera F, Seydoux J, Geloen A, et al.: Angiotensinogendeficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001, 142:5220–5225.PubMedCrossRefGoogle Scholar
  73. 73.
    Folli F, Kahn R, Hansen H, et al.: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 1997, 100:2158–2169.PubMedCrossRefGoogle Scholar
  74. 74.
    Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and sympathetic adrenal system. N Engl J Med 1996, 334:374–381.PubMedCrossRefGoogle Scholar
  75. 75.
    Sowers JR: Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997, 29:691–699. This paper reviews the current understanding of mechanisms of the hemodynamic, metabolic, and growth effects of insulin and IGF-1 exerted on cardiovascular tissue. It provides a clear scientific explanation of these effects in hyperinsulinemia and the insulin-resistant state. Further, it gains its particular importance from tackling both normal and pathologic aspects of insulin and IGF-1 actions.PubMedGoogle Scholar
  76. 76.
    Sowers JR, Bakris GL: Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000, 342:969–970.PubMedCrossRefGoogle Scholar
  77. 77.
    Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Food and Nutrition Board (FNB), Institute of Medicine (IOM); 2002.Google Scholar
  78. 78.
    Reaven G, Segal K, Hauptman J, et al.: Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001, 87:827.PubMedCrossRefGoogle Scholar
  79. 79.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  80. 80.
    Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Jonathan P. Castro
    • 1
  • Fadi A. El-Atat
    • 1
  • Samy I. McFarlane
    • 1
  • Ashish Aneja
    • 1
  • James R. Sowers
    • 1
  1. 1.Division of Endocrinology, Diabetes and HypertensionState University of New York Downstate and Brooklyn Veterans Affairs Medical CenterBrooklynUSA

Personalised recommendations